[B01AD01, streptokinase, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Streptokinase.]
[B01AE07, dabigatran etexilate, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Dabigatran etexilate.]
[B02AB01, aprotinin, Aprotinin may increase the thrombogenic activities of Von Willebrand factor human.]
[B02AA02, tranexamic acid, Tranexamic acid may increase the thrombogenic activities of Von Willebrand factor human.]
[B01AD04, urokinase, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Urokinase.]
[B01AF01, rivaroxaban, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Rivaroxaban.]
[B01AC24, ticagrelor, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Ticagrelor.]
[B01AC13, abciximab, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Abciximab.]
[S01XA13, alteplase, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Alteplase.]
[B01AC09, epoprostenol, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Epoprostenol.]
[B02AA01, 6-aminocaproic acid, The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Von Willebrand factor human.]
[B01AA03, warfarin, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Warfarin.]
[B01AE01, desirudin, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Lepirudin.]
[B01AX01, defibrotide, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Defibrotide.]
[B01AF02, apixaban, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Apixaban.]
[B02AA03, 4-aminomethylbenzoic acid, Aminomethylbenzoic acid may increase the thrombogenic activities of Von Willebrand factor human.]
[B01AE03, argatroban, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Argatroban.]
[B01AC26, vorapaxar, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Vorapaxar.]
[B01AA07, acenocoumarol, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Acenocoumarol.]
[B01AA01, dicumarol, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Dicoumarol.]
[B01AF03, edoxaban, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Edoxaban.]
[B01AA11, tioclomarol, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Tioclomarol.]
[B01AC25, cangrelor, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Cangrelor.]
[B01AF04, betrixaban, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Betrixaban.]
[B01AE02, lepirudin, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Lepirudin.]
[B01AD11, tenecteplase, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Tenecteplase.]
[B01AB12, bemiparin, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Bemiparin.]
[B01AX05, fondaparinux, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Fondaparinux.]
[B01AC07, dipyridamole, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Dipyridamole.]
[B01AD10, drotrecogin alfa, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Drotrecogin alfa.]
[B01AC18, triflusal, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Triflusal.]
[C05CA04, troxerutin, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Troxerutin.]
[B01AD03, anistreplase, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Anistreplase.]
[B05AA05, dextran, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Dextran.]
[B01AD05, plasmin, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Fibrinolysin.]
[B01AA12, fluindione, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Fluindione.]
[S01XA14, heparin, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Heparin.]
[B02AB02, alpha 1-antitrypsin, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Von Willebrand factor human.]
[S02AA06, hydrogen peroxide, Hydrogen peroxide may increase the thrombogenic activities of Von Willebrand factor human.]
[B05CB02, sodium citrate, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Sodium citrate.]
[B01AE06, bivalirudin, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Bivalirudin.]
[B01AC22, prasugrel, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Prasugrel.]
[B01AB06, nadroparin, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Nadroparin.]
[B01AB05, enoxaparin, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Enoxaparin.]
[B01AB04, dalteparin, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Dalteparin.]
[B02BA02, vitamin K3, Menadione may increase the thrombogenic activities of Von Willebrand factor human.]
[B01AB07, parnaparin, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Parnaparin.]
[B01AB10, tinzaparin, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Tinzaparin.]
[B01AB08, reviparin, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Reviparin.]
[B01AD07, reteplase, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Reteplase.]
[B01AD09, ancrod, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Ancrod.]
[B01AB09, danaparoid, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Danaparoid.]
[B01AA02, phenindione, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Phenindione.]
[B01AA04, phenprocoumon, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Phenprocoumon.]
